US Supplement Industry Needs Relief From ‘Drug Preclusion’ Policy, CRN Reminds FDA

CRN petition argues against general preclusion while NPA petition addressed specifically FDA’s wielding of the provision to prohibit the use of NMN supplements available in US. “FDA has acknowledged that they really can't answer one without answering. The two are inextricably linked,” says CRN CEO Steve Mister.

(Source: Shutterstock/Citeline)

More from Regulation

More from HBW Insight